Bellicum Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bellicum Pharmaceuticals Inc (BLCM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Bellicum Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 2M vs 537,905M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+164.0% annualized vs trailing 12 months), vs decelerating (-46.1%) for its tracked peer group.
- Growth: Bellicum Pharmaceuticals Inc generated -0.9% revenue growth year over year in Q3 2023, vs 2.1% for its competitors combined.
- Profitability: Its -76.2% net margin compares with 46.5% for the peer group.
- Peer revenue share: Bellicum Pharmaceuticals Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.02M compares with $1.00M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BLCM Sales vs. its Competitors, Q3 2023
Bellicum Pharmaceuticals Inc reported revenue contraction of 0.89 % year on year in Q3 2023, below its competitors' combined revenue growth of 2.09 %.
With a net margin of -76.15 %, Bellicum Pharmaceuticals Inc reported lower profitability than its competitors (46.48 %).
Bellicum Pharmaceuticals Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
API endpoints for this dataset
Bellicum Pharmaceuticals Inc vs. its Competitors, Q3 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Bellicum Pharmaceuticals Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Bellicum Pharmaceuticals Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Bellicum Pharmaceuticals Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Bellicum Pharmaceuticals Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs -0.9% for Bellicum Pharmaceuticals Inc. Bellicum Pharmaceuticals Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Bellicum Pharmaceuticals Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bellicum Pharmaceuticals Inc | No | - | - | No |
| Competitors combined (141) | ||||
| High-Confidence Competitors (5) | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BLCM Stock Performance relative to its Competitors
BLCM Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 3 | Rallybio Corporation | 282.9% | Outperformed |
| 4 | Nuvectis Pharma inc | 282.9% | Outperformed |
| 5 | 180 Life Sciences Corp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Bellicum Pharmaceuticals Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Bellicum Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Bellicum Pharmaceuticals Inc |
2.31 | 1.52 |
 Eli Lilly And Company |
1,279,607.89 | 86,462.00 |
 Johnson and Johnson |
687,517.91 | 99,335.00 |
 Merck and Co Inc |
365,658.80 | 66,569.00 |
 Novartis Ag |
319,173.30 | 56,674.00 |
 Astrazeneca Plc |
291,719.12 | 58,739.00 |
| SUBTOTAL | 3,706,776.66 | 568,074.21 |
Sign in to see all competitors of Bellicum Pharmaceuticals Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Bellicum Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Bellicum Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from Bellicum Pharmaceuticals Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Cell Source Inc | Company report | 85% |
| Gritstone Bio Inc | Company report | 85% |
| Quoin Pharmaceuticals Ltd | Company report | 85% |
| Immunitybio inc | Company report | 85% |
| Precigen Inc | Company report | 85% |
| Celyad Oncology Sa | Company report | 85% |
| Tscan Therapeutics Inc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Vor Biopharma Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Adicet Bio Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| 2seventy Bio Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Alaunos Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Bellicum Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Bellicum Pharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Bellicum Pharmaceuticals Inc .
Bellicum Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Bellicum Pharmaceuticals Inc | 2 | 21,083 | 36,014 |
| Eli Lilly And Company | 1,279,608 | 1,729,240 | 551,594 |
| Johnson and Johnson | 687,518 | 705,504 | 114,311 |
| Merck and Co Inc | 365,659 | 887,587 | 42,267 |
| Novartis Ag | 319,173 | 752,973 | 185,566 |
| Astrazeneca Plc | 291,719 | 706,847 | 123,141 |
| PEERS TOTAL | 3,706,774 | 1,001,085 | 154,494 |
Sign in to see all peers for Bellicum Pharmaceuticals Inc .
Bellicum Pharmaceuticals Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Bristol myers Squibb Company | United States 69.43 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Bellicum Pharmaceuticals Inc .
Bellicum Pharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (446 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.5x | - |
| EV / EBITDA | 0.0x | 15.4x | -15.4x |
| P/B | -0.9x | 4.2x | -5.1x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -9.78 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Bellicum Pharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | - | -52.32 % | 500.00 % | 108.85 % | -89.10 % | 500.00 % | -75.32 % |
| Operating Margin | -17,623.71 % | -47,236.22 % | -2,347.33 % | -1,028.54 % | - | - | - |
| Return on Invested Capital | -26.61 % | -33.81 % | -46.11 % | -118.42 % | - | - | -67.51 % |
| P/E | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Bellicum Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+164.0% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
- A meaningful share of competitors (58.70 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-46.1% annualized).
Methodology: see Methodology: SWOT Analysis.
Bellicum Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Bellicum Pharmaceuticals Inc | 0.58 | 0.65 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
Sign in to see all peers for Bellicum Pharmaceuticals Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Bellicum Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Bellicum Pharmaceuticals Inc | Q3 2023 | -0.9 % | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| PEERS TOTAL | +10.5 % | +4.5 % |
Sign in to see all peers for Bellicum Pharmaceuticals Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Bellicum Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Bellicum Pharmaceuticals Inc | Q3 2023 | - | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
Sign in to see all peers for Bellicum Pharmaceuticals Inc .
Bellicum Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Bellicum Pharmaceuticals Inc | 18.30% | 19.61% | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
Sign in to see all peers for Bellicum Pharmaceuticals Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Bellicum Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Bellicum Pharmaceuticals Inc | - | 1.52 |
| Eli Lilly And Company | 46.50 | 14.80 |
| Johnson and Johnson | 42.48 | 6.92 |
| Merck and Co Inc | 119.39 | 5.49 |
| Novartis Ag | 22.82 | 5.63 |
| Astrazeneca Plc | 28.56 | 4.97 |
| PEERS AVERAGE | 42.28 | 6.53 |
Sign in to see all peers for Bellicum Pharmaceuticals Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.